Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
541. |
ECCT/25/07/01 | FIH Study of CLY-124 A Phase 1, Randomized, Placebo-Controlled, Double Blind, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CLY-124 in Healthy Volunteers and Participants with Sickle Cell Disease |
Principal Investigator(s) 1. Bernhards Ogutu Site(s) in Kenya 1. Strathmore University Medical Center [SUMC], Creates for Research in Therapeutic Sciences (Nairobi City county) 2. Victoria Biomedical Research Institute [VIBRI] (Kisumu county) |
18-12-2025 |
View |
542. |
ECCT/25/02/01 | IMPAACT 2037 Open-Label, Phase I Study of the Safety and Pharmacokinetics of PGT121.414.LS alone and in combination with VRC07-523LS in Infants Exposed to HIV-1 |
Principal Investigator(s) 1. Lucy C. Koech Site(s) in Kenya Kenya Medical Research Institute/Walter Reed Project |
18-12-2025 |
View |
543. |
ECCT/25/05/01 | Sparkle Study Site 1403 A phase III, Multicenter, Randomized, Placebo Controlled, Double blind Study to Assess Efficacy and Safety of Crizanlizumab (5 mg/kg) versus placebo, with or without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Frequent Vaso-Occlusive CrisesA phase III, Multicenter, Randomized, Placebo Controlled, Double blind Study to Assess Efficacy and Safety of Crizanlizumab (5 mg/kg) versus placebo, with or without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Frequent Vaso-Occlusive Crises |
Principal Investigator(s) 1. Fredrick Chite Asirwa Site(s) in Kenya 1. Victoria Biomedical Research Institute (Kisumu county) 2. Ahero Clinical trials Unit (Kisumu county) 3. International Cancer institute (Uasin Gishu county) 4. Kondele Childrens Hospital (Kisumu county) 5. KEMRI/CRDR KEMRI Clinical Research Annex (Siaya county) 6. Gertrudes Children’s Hospital (Nairobi City county) |
18-12-2025 |
View |
544. |
ECCT/25/09/01 | VLA1553-404 VLA1553-404: A Pragmatic Randomised Controlled Trial to Evaluate the Effectiveness and Safety of VLA1553 against Chikungunya Virus Disease |
Principal Investigator(s) 1. Prof. Videlis Nduba Site(s) in Kenya 1. KEMRI-MTWAPA (Kilifi county) |
21-01-2026 |
View |
545. |
ECCT/25/10/01 | H06_04TP A Phase 2, open-label, single-center, long-term immunogenicity follow-up study of the GVGH altSonflex1-2-3 Shigella vaccine 1, 2 and 3 years after vaccination in African children. |
Principal Investigator(s) 1. Deborah Chepngeno Langat Site(s) in Kenya KEMRI CRC WRP KERICHO |
01-02-2026 |
View |
546. |
ECCT/25/05/11 | Sparkle study site-1406 A phase III, Multicenter, Randomized, Placebo Controlled, Double blind Study to Assess Efficacy and Safety of Crizanlizumab (5 mg/kg) versus placebo, with or without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Frequent Vaso-Occlusive Crises |
Principal Investigator(s) 1. Doreen Mutua Site(s) in Kenya 1. Victoria Biomedical Research Institute (Kisumu county) 2. Ahero Clinical trials Unit (Kisumu county) 3. International Cancer institute (Uasin Gishu county) 4. Kondele Childrens Hospital (Kisumu county) 5. KEMRI/CRDR KEMRI Clinical Research Annex (Siaya county) 6. Gertrudes Children’s Hospital (Nairobi City county) |
03-02-2026 |
View |
547. |
ECCT/25/08/05 | Floral roll over study An open-label, multi-centre, rollover study to characterise long-term safety and efficacy of etavopivat in adults, adolescents and children who have sickle cell disease or thalassaemia and have completed a treatment period in an etavopivat study. |
Principal Investigator(s) 1. Dr. Isaac Tsikhutsu Site(s) in Kenya 1. KEMRI WALTER REED KERICHO (Kericho county) 2. Center for Research in Therapeutic Sciences (CREATES) (Kisumu county) 3. KEMRI Siaya Clinical Research Annex (Siaya county) 4. Gertrudes Childrens Hospital (Nairobi City county) 5. KEMRI/ WRAIR-Africa, Kombewa Clinical Research Center (Kisumu county) 6. KEMRI/ WRAIR-Africa, Kombewa Clinical Research Center (Kisumu county) 7. KEMRI Kondele Children\'s Hospital (Kisumu county) |
09-02-2026 |
View |
548. |
ECCT/25/11/03 | RSV IMPACT TRIAL A Phase-IIIb individually randomized, placebo-controlled trial on safety of RSVA/B-preF vaccine in pregnant women and efficacy against severe RSV-associated lower respiratory tract infection in infants. |
Principal Investigator(s) 1. Nancy A. Otieno 2. Evans M. Ogoti Site(s) in Kenya Kenya Medical Research Institute, Centre for Global Health Research - Siaya (KE1) |
09-02-2026 |
View |
549. |
ECCT/25/11/07 | MK-8527 as HIV-1 PrEP Protocol Title: A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis |
Principal Investigator(s) 1. John Mark Ayallo 2. Kelvin Jerry Wandera 3. John Okanda 4. Joash Diemo 5. Tobias Odwar 6. Jacob Onyango Site(s) in Kenya 1. Kenya Impact Research and Development Organization (K-IRDO) (Kisumu county) 2. Nyanza Reproductive Health Society (NRHS), UNIM Research and Training Center (URTC) (Kisumu county) 3. Partners for Health and Development in Africa – Sex workers Outreach Program (PHDA – SWOP) (Nairobi City county) |
09-02-2026 |
View |
550. |
ECCT/25/09/03 | PRESERVE Partial breast re-irradiation using ultra hypofractionation (PRESERVE) Phase 2 multi-institutional study |
Principal Investigator(s) 1. Angela Waweru Site(s) in Kenya Aga Khan University Hospital |
09-02-2026 |
View |